Sars cov 2 igg

Anti-SARS-CoV-S1-IgG was determined using a commercially available assay detecting IgG antibodies against S1-RBD (SARS-CoV-2 IgG, Siemens™, Munich, Germany). Anti-S1-IgG titers of >21.8 BAU/mL were classified as a humoral response.

We obtained donor blood samples from individuals who were recruited under University of Utah Institutional Review Board (IRB) protocol 131664. These individuals were recruited from Salt Lake City, UT and the surrounding metropolitan area between May of 2020 and December of 2021. Informed consent was obtained from all individual participants included in the study. The de-identified specimens were blinded during collection and analysis. Whole blood samples were drawn from 18 convalescent COVID-19 patients and 31 healthy individuals in parallel. The clinical samples were obtained from convalescent patients who exhibited a mild form of the disease and did not require hospitalization. For convalescent patients, specimens were collected approximately two to four weeks after disease onset. Donors reported no symptoms at the time of sample collection. The COVID-19 patients ranged in age from 19 to 65 years old (43.3 y/o mean), representing different races and genders. The healthy control individuals ranged in age from 19 to 71 years old (38.5 y/o mean), representing different races and genders (Table 1). SARS-CoV-2 infection was assessed by one or more immunologic (Abbott Architect SARS-CoV-2 IgG, Euroimmun Anti-SARS-CoV-2 ELISA, or Siemens SARS-CoV-2 IgG) (38 (link)) or molecular assays.

Blood samples in this study were obtained from Associated Regional and University Pathologists, Inc. (ARUP) Laboratories. In all cases, samples were de-identified. Samples were tested for one or a combination of the following assays: Abbott Architect SARS-CoV-2 IgG, specific for nucleocapsid; Euroimmun Anti-SARS-CoV-2 ELISA (IgG), specific for the S1 domain of the spike glycoprotein; Siemens SARS-CoV-2 IgG, specific for RBD-binding IgG; PCR test specific for viral nucleic acid (ARUP Laboratories). Five pre-pandemic serum samples (Flu#1–5) were archived and were from patients hospitalized for severe flu respiratory infections in 2016.